Research Issues 26
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
AND DRUG' ABUSE' ( , \ I ., : for VOLUNTEER .AFTERCARE OFFICERS
=£q, G& ~. ~I o II g ~ L>- ".,-~..- ". 'PR'OBATIQN AND AFTERCA'RE SERVICE " rI ! ,~ i I!' 0 i! ,1 u I', :( ~ II' 1 r :.:" I I) 'tbLLECTED ,READINGS ,~ ~ - '., ,\ ON It, DR!J.GS ·AND DRUG' ABUSE' ( , \ i ., : FOR VOLUNTEER .AFTERCARE OFFICERS. ri ll, "' , 'I: o '.> .. , 4 . , . I:o..-__________:i-.._---... __ ~~ ___~;L __~ ______ fF PROBATION AND AFTERCARE SERVICE COLLECTED READUNGS ON DRUGS AND DRUG ABUSE FOR VOLUNTEER AFTERCARE OFFICERS 1977 a If' t «(, CONTENTS ARTICLE PAGE PART I - THE DRUG SCENE Speech by Dr Goh Keng Swee, Deputy Prime Minister and Minister of Defence, at the Launching of the NADAC Month at the National Theatre Or! Wedr!e~dev, 4th August 1976. 1 II Speech by Mr Chua Sian Chin, Minister for Home Affairs and Education at the Opening Ceremony of the First Meeting of ASEAN Drug Experts at the Crystal Ballroom, Hyatt Hotel, on Tuesday, 26th October 1976. 6 PART II - PREVENTIVE EDUCATION III The Objectives of Anti-Drug Abuse Education by Dr Tow Siang Hwa, Past President, Singapore Anti-Narcotics Association 8 .. PART III - DRUGS AND THEIR EFFECTS IV CommonlY Abused Drugs by Dr Yeow Teow Seng, Associate Profassor oi Pharmacology, University of Singapore 12 V The Non-Medical Uses of Dependence-Producing Drugs by Dr Leong Hon Koon 18 VI Psychiatric Aspects of Drug Abuse by Dr Paul W Ngui, Consultant Psychlatrist 23 VII Sad End to All Drug Trips by Dr Chao Tzu Cheng, Senior Forensic Pathologist, Ministry of Health 27 PART IV - SOCIAL CONSIDERATIONS OF DRUG ABUSE VIII Patterns & Social Consequences of Drug Abuse & the Rehabilitation of Drug Addict by K V Veloo, Chief Probation & Aftercare Officer 29 IX Social Factors of Drug Abuse by K V Veloo, Chief Probation & Aftercare Officer 34 f X Some Causes of Adolescent Problems , by S Vasoo, Deputy Director, Singapore Council of Social Service 39 " ,. -
MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated. -
Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update
PAIN MANAGEMENT/CONCEPTS Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update Steven M. Green, MD, Mark G. Roback, MD, Robert M. Kennedy, MD, Baruch Krauss, MD, EdM From the Department of Emergency Medicine, Loma Linda University Medical Center and Children’s Hospital, Loma Linda, CA (Green); the Department of Pediatrics, University of Minnesota, Minneapolis, MN (Roback); the Division of Emergency Medicine, St. Louis Children’s Hospital, Washington University, St. Louis, MO (Kennedy); and the Division of Emergency Medicine, Children’s Hospital Boston and Department of Pediatrics, Harvard Medical School, Boston, MA (Krauss). We update an evidence-based clinical practice guideline for the administration of the dissociative agent ketamine for emergency department procedural sedation and analgesia. Substantial new research warrants revision of the widely disseminated 2004 guideline, particularly with respect to contraindications, age recommendations, potential neurotoxicity, and the role of coadministered anticholinergics and benzodiazepines. We critically discuss indications, contraindications, personnel requirements, monitoring, dosing, coadministered medications, recovery issues, and future research questions for ketamine dissociative sedation. [Ann Emerg Med. 2011;xx:xxx.] 0196-0644/$-see front matter Copyright © 2011 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2010.11.030 INTRODUCTION thalamocortical and limbic systems, effectively dissociating the The dissociative -
(12) Patent Application Publication (10) Pub. No.: US 2016/017.4603 A1 Abayarathna Et Al
US 2016O174603A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/017.4603 A1 Abayarathna et al. (43) Pub. Date: Jun. 23, 2016 (54) ELECTRONIC VAPORLIQUID (52) U.S. Cl. COMPOSITION AND METHOD OF USE CPC ................. A24B 15/16 (2013.01); A24B 15/18 (2013.01); A24F 47/002 (2013.01) (71) Applicants: Sahan Abayarathna, Missouri City, TX 57 ABSTRACT (US); Michael Jaehne, Missouri CIty, An(57) e-liquid for use in electronic cigarettes which utilizes- a TX (US) vaporizing base (either propylene glycol, vegetable glycerin, (72) Inventors: Sahan Abayarathna, MissOU1 City,- 0 TX generallyor mixture at of a 0.001 the two) g-2.0 mixed g per with 1 mL an ratio. herbal The powder herbal extract TX(US); (US) Michael Jaehne, Missouri CIty, can be any of the following:- - - Kanna (Sceletium tortuosum), Blue lotus (Nymphaea caerulea), Salvia (Salvia divinorum), Salvia eivinorm, Kratom (Mitragyna speciosa), Celandine (21) Appl. No.: 14/581,179 poppy (Stylophorum diphyllum), Mugwort (Artemisia), Coltsfoot leaf (Tussilago farfara), California poppy (Eschscholzia Californica), Sinicuichi (Heimia Salicifolia), (22) Filed: Dec. 23, 2014 St. John's Wort (Hypericum perforatum), Yerba lenna yesca A rtemisia scoparia), CaleaCal Zacatechichihichi (Calea(Cal termifolia), Leonurus Sibericus (Leonurus Sibiricus), Wild dagga (Leono Publication Classification tis leonurus), Klip dagga (Leonotis nepetifolia), Damiana (Turnera diffiisa), Kava (Piper methysticum), Scotch broom (51) Int. Cl. tops (Cytisus scoparius), Valarien (Valeriana officinalis), A24B 15/16 (2006.01) Indian warrior (Pedicularis densiflora), Wild lettuce (Lactuca A24F 47/00 (2006.01) virosa), Skullcap (Scutellaria lateriflora), Red Clover (Trifo A24B I5/8 (2006.01) lium pretense), and/or combinations therein. -
Substance Abuse and Dependence
9 Substance Abuse and Dependence CHAPTER CHAPTER OUTLINE CLASSIFICATION OF SUBSTANCE-RELATED THEORETICAL PERSPECTIVES 310–316 Residential Approaches DISORDERS 291–296 Biological Perspectives Psychodynamic Approaches Substance Abuse and Dependence Learning Perspectives Behavioral Approaches Addiction and Other Forms of Compulsive Cognitive Perspectives Relapse-Prevention Training Behavior Psychodynamic Perspectives SUMMING UP 325–326 Racial and Ethnic Differences in Substance Sociocultural Perspectives Use Disorders TREATMENT OF SUBSTANCE ABUSE Pathways to Drug Dependence AND DEPENDENCE 316–325 DRUGS OF ABUSE 296–310 Biological Approaches Depressants Culturally Sensitive Treatment Stimulants of Alcoholism Hallucinogens Nonprofessional Support Groups TRUTH or FICTION T❑ F❑ Heroin accounts for more deaths “Nothing and Nobody Comes Before than any other drug. (p. 291) T❑ F❑ You cannot be psychologically My Coke” dependent on a drug without also being She had just caught me with cocaine again after I had managed to convince her that physically dependent on it. (p. 295) I hadn’t used in over a month. Of course I had been tooting (snorting) almost every T❑ F❑ More teenagers and young adults die day, but I had managed to cover my tracks a little better than usual. So she said to from alcohol-related motor vehicle accidents me that I was going to have to make a choice—either cocaine or her. Before she than from any other cause. (p. 297) finished the sentence, I knew what was coming, so I told her to think carefully about what she was going to say. It was clear to me that there wasn’t a choice. I love my T❑ F❑ It is safe to let someone who has wife, but I’m not going to choose anything over cocaine. -
Cannabis (Sub)Culture, the Subcultural Repository, and Networked Mediation
SIMULATED SESSIONS: CANNABIS (SUB)CULTURE, THE SUBCULTURAL REPOSITORY, AND NETWORKED MEDIATION Nathan J. Micinski A Thesis Submitted to the Graduate College of Bowling Green State University in partial fulfillment of the requirements for the degree of MASTER OF ARTS May 2014 Committee: Ellen Berry, Advisor Rob Sloane © 2014 Nathan Micinski All Rights Reserved iii ABSTRACT Ellen Berry, Advisor Subcultural theory is traditionally rooted in notions of social deviance or resistance. The criteria for determining who or what qualifies as subcultures, and the most effective ways to study them, are based on these assumptions. This project seeks to address these traditional modes of studying subcultures and discover ways in which their modification may lead to new understandings and ways of studying subcultures in the contemporary moment. This will be done by suggesting a change in the criteria of examining subcultures from that of deviance or resistance to identification with a collection of images, symbols, rituals, and narratives. The importance of this distinction is the ability to utilize the insights that studying subcultures can offer while avoiding the faults inherent in speaking for or at a subculture rather than with or from it. Beyond addressing theoretical concerns, this thesis aims to apply notions of subcultural theory to study the online community of Reddit, in particular, a subset known as r/trees–a virtual repository for those images, symbols, rituals, and narratives of cannabis subculture. R/trees illustrates the life and vibrancy of a unique subcultural entity, which to this point has evaded a cultural studies analysis. To that end, this project advocates for the importance of the cultural studies approach to analyzing cannabis subculture and further, to insert the findings of this study into that gap in the literature. -
Sílvia Vilares Conde
Sílvia Vilares Conde FUNCTIONAL SIGNIFICANCE OF ADENOSINE IN CAROTID BODY CHEMOSENSORY ACTIVITY IN CONTROL AND CHRONICALLY HYPOXIC ANIMALS Lisboa, 2007 a Dissertation presented to obtain the PhD degree in “Ciências da Vida – Especialidade Farmacologia” at the Faculdade de Ciências Médicas, Universidade Nova de Lisboa and Biotecnología: Aplicaciones Biomédicas at the Facultad de Medicina, Universidad de Valladolid Supervised by Profs. Constancio Gonzalez, Emília Monteiro and Ana Obeso. b Realizado com o apoio da Fundação para a Ciência e Tecnologia, SFRH/BD/14178/2003 financiada pelo POCI 2010 no âmbito da Formação avançada para a Ciência, Medida IV.3. c To my mum and dad d This work: Originated the following publications: - Conde S.V., Obeso A., Vicario I., Rigual R., Rocher A. and Gonzalez C. (2006), Caffeine inhibition of rat carotid body chemoreceptors is mediated by A2A and A2B adenosine receptors, J. Neurochem., 98, 616-628. (Chapter 3) - Conde S.V. and Monteiro E.C. (2006), Activation of nicotinic ACh receptors with α4 subunits induces adenosine release at the rat carotid body, Br. J. Pharmacol., 147, 783-789. (Chapter 2) - Conde S.V. and Monteiro E.C. (2004), Hypoxia induces adenosine release from the rat carotid body, J. Neurochem., 89 (5), 1148-1156. (Chapter 1) - Conde S.V. and Monteiro E.C. (2003), Adenosine-acetylcholine interactions at the rat carotid body, In: “Chemoreception: From cellular signalling to functional plasticity”, JM Pequinot et al. (Eds), Klumer Academic Press London, 305-311. (Chapter 2) Won the following awards: - 1st Prize “De Castro-Heymans–Neil Award” awarded by ISAC (International Society for Arterial Chemoreception) to the best work presented by a Young Researcher each triennial ISAC Meeting, 2002 - Pfizer Honor Young Researcher Prize awarded by the Portuguese Society of Medical Sciences, 2002 e Functional significance of adenosine in carotid body chemoreception PhD thesis, Silvia Vilares Conde INDEX Page List of Figures and Tables……………………………………………………….. -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
Lactuca Sativa
Botanical Files on Lettuce (Lactuca sativa). On the chance for flow between wild and cultivated gene Lettuce (Lactuca sativa L. including L. serriola L., Compositae) and the generalized implications for risk-assessments on genetically modified plants by 12 2 ,3 F.T.+Frietema de Vriesi R. van der Meijdeni and W.A. Brandenburg , dit onderzoek werd door het Ministerie De opdracht tot gegeven van Volkshuisvesting, Ruimtelijke Ordening & Milieu, Directoraat-Generaal Milieu, Directie Stoffen, Veiligheid, Straling. De tekst het zal in de VROM/DGM Risico- van rapport verschijnen publicatiereeks beoordeling genetisch gemodificeerde organismen. This commissioned the Netherlands of report was by Ministry Housing, Spatial Planning and Environment, Directorate General for the Environment, Directorate for Chemicals, External Safety and Radiation Protection, P. O. Box 450, 2260 MB Leidschendam, The Netherlands. It will be published in the series Risk Assessment Genetically Modified Organisms. 1) Formerly F.T. de Vries 2) Rijksherbarium/Hortus Botanicus, Slate University Leiden, P.O. Box 9514, 2300 RA Leiden, The Netherlands 3) Centrum voor Plantenveredelings- en Reproduktieonderzoek, CPRO-DLO, P.O. Box 16, 6700 AA Wageningen,The Netherlands Contents Summary 3 1. Introduction 3 2. Lactuca serriolaL. and L. serriola L. in Western 6 Historical part: Europe... Introduction 6 Terminology 6 The genus Lactuca L 7 Genetics 8 Ancestors 9 Characters 9 3. Domestication of Lettuce 11 Introduction 11 Early domestication 11 of the different of cultivated lettuce Further development groups 12 4. Field trial 13 Introduction 13 Material 15 Methods 15 Observations 16 Herbarium material 16 Photography and microscopy 16 5. Results 17 Introduction 17 Results herbarium study 17 Results field trial 17 6. -
A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L
Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A. -
Innovation in Pain Management
INNOVATION IN PAIN MANAGEMENT The transcript of a Witness Seminar held by the Wellcome Trust Centre for the History of Medicine at UCL, London, on 12 December 2002 Edited by L A Reynolds and E M Tansey Volume 21 2004 ©The Trustee of the Wellcome Trust, London, 2004 First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2004 The Wellcome Trust Centre for the History of Medicine at University College London is funded by the Wellcome Trust, which is a registered charity, no. 210183. ISBN 978 0 85484 097 7 Histmed logo images courtesy Wellcome Library, London. Design and production: Julie Wood at Shift Key Design 020 7241 3704 All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/ Please cite as: Reynolds L A, Tansey E M. (eds) (2004) Innovation in Pain Management. Wellcome Witnesses to Twentieth Century Medicine, vol. 21. London: Wellcome Trust Centre for the History of Medicine at UCL. CONTENTS Illustrations and credits v Witness Seminars: Meetings and publications;Acknowledgements vii E M Tansey and L A Reynolds Introduction Christina Faull xix Transcript Edited by L A Reynolds and E M Tansey 1 Appendix 1 73 Extract from an annotated Physiological Society interview with Patrick Wall (1925–2001) by Martin Rosenberg and Steve McMahon (5 February 1999) Appendix 2 83 Morphine: Optimal potential for benefit with a minimum risk of adverse events and burden by Jan Stjernswärd (12 April 2004) References 85 Biographical notes 103 Index 115 Key to cover photographs ILLUSTRATIONS AND CREDITS Figure 1 Dr Cicely Saunders and two patients at St Joseph’s on their golden wedding anniversary, 1960. -
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.